Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fosaprepitant
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Techdow USA
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, CTTQ will manufacture Fosaprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist, for Injection, the therapeutic generic equivalent of Emend, and will be sold under the Techdow USA Label.
Brand Name : Emend-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 22, 2023
Lead Product(s) : Fosaprepitant
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Techdow USA
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
